Intersect ENT, Inc. (XENT) |
|
28.24 0 (0%)
|
12-31 19:00 |
|
Open: |
28.25 |
Pre. Close: |
28.24 |
|
High:
|
28.25 |
Low:
|
28.23 |
|
Volume:
|
0 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2022-11-18 4:26:28 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 32.99 One year: 38.53 |
| Support: |
Support1: 28.23 Support2: 28.22 |
| Resistance: |
Resistance1: 28.25 Resistance2: 32.99 |
| Pivot: |
28.23 |
| Moving Average: |
MA(5): 28.23 MA(20): 28.23
MA(100): 28.23 MA(250): 27.87  |
| MACD: |
MACD(12,26): 0  Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 50 %D(3): 50 |
| RSI: |
RSI(14): 64.9 |
| 52-week: |
High: 28.25 Low: 26.75 |
| Average Vol(K): |
3-Month: 0 (K) 10-Days: 0 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ XENT ] has closed Bollinger Bands are 0% narrower than normal. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
28.32 - 28.46 |
28.46 - 28.57 |
|
Low:
|
27.83 - 28.03 |
28.03 - 28.19 |
|
Close:
|
27.97 - 28.26 |
28.26 - 28.5 |
|
Company Description |
|
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California. |
Headline News |
Thu, 17 Nov 2022
SMEs challenged to set eyes on higher productivity, new markets - Capital FM Kenya
Mon, 16 May 2022
Merger Arbitrage Mondays: Chicken Soup Acquires Redbox At A Massive Discount (CSSE) - Seeking Alpha
Fri, 13 May 2022
Medtronic (MDT) completes acquisition of Intersect ENT (XENT) - StreetInsider.com
Tue, 10 May 2022
Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates - Yahoo Finance
Tue, 25 Jan 2022
Real-World Evidence Study Demonstrates Intersect ENT's PROPEL® Sinus Implant Reduces Healthcare Resource Utilization - Business Wire
Fri, 06 Aug 2021
Medtronic to acquire Intersect ENT in $1.1B deal - Mass Device
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
33 (M) |
| Shares Float |
28 (M) |
|
% Held by Insiders
|
1.5 (%) |
|
% Held by Institutions
|
93.5 (%) |
|
Shares Short
|
3,220 (K) |
|
Shares Short P.Month
|
2,030 (K) |
Stock Financials |
|
EPS
|
-2.69 |
|
EPS Est Next Qtl
|
-0.11 |
|
EPS Est This Year
|
-0.62 |
|
EPS Est Next Year
|
-0.39 |
|
Book Value (p.s.)
|
0.49 |
|
Profit Margin (%)
|
-149.6 |
|
Operating Margin (%)
|
-65.3 |
|
Return on Assets (ttm)
|
-23.3 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
8.6 |
|
Gross Profit (p.s.)
|
2.29 |
|
Sales Per Share
|
3.19 |
|
EBITDA (p.s.)
|
-1.94 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-59 (M) |
|
Levered Free Cash Flow
|
-31 (M) |
Stock Valuations |
|
PE Ratio
|
-10.54 |
|
PEG Ratio
|
-2.3 |
|
Price to Book value
|
57.63 |
|
Price to Sales
|
8.85 |
|
Price to Cash Flow
|
-15.89 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
